A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011

Virology Journal

Volumn 9, Issue , 2012, Pages

  Yu, Bin ^a   Wang, Zhen ^a   Dong, Jianing ^a   Wang, Chu ^a   Gu, Lina ^a   Sun, Caijun ^b   Kong, Wei ^a   Yu, Xianghui ^a  

^a JILIN UNIVERSITY   (China)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

Adenovirus; HIV vaccine; Neutralizing antibodies; Seroprevalence

Indexed keywords

ADENOVIRUS VECTOR; ALKALINE PHOSPHATASE; MATERNAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ARTICLE; CHILD; CHINA; GENE THERAPY; HUMAN; HUMAN ADENOVIRUS 2; HUMAN ADENOVIRUS 5; PRESCHOOL CHILD; SCHOOL CHILD; SEROLOGY;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; AGE FACTORS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; SEROEPIDEMIOLOGIC STUDIES; SEROTYPING;

ADENOVIRIDAE; HUMAN ADENOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84869877136     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-287     Document Type: Article

References (26)

1. Adenoviridae: The viruses and their replication. Berk A, Fields virology Lippincott Williams & Wilkins, Philadelphia, PA, Knipe DM HP, 5 2007 2355 2394
2. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Seregin SS, Amalfitano A, Expert Opin Biol Ther 2009 9 1521 1531 10.1517/14712590903307388 19780714
3. New insights on adenovirus as vaccine vectors. Lasaro MO, Ertl HC, Mol Ther 2009 17 1333 1339 10.1038/mt.2009.130 19513019
4. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ, J Virol 2003 77 799 803 10.1128/JVI.77.1.799-803.2003 12477888 (Pubitemid 36005022)
5. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, et al. Nature 2006 441 239 243 10.1038/nature04721 16625206
6. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, et al. Clin Infect Dis 2008 46 1769 1781 10.1086/587993 18433307 (Pubitemid 351706778)
7. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, Kostense S, Penders G, Helmus N, Koudstaal W, et al. J Virol 2003 77 8263 8271 10.1128/JVI.77.15.8263-8271.2003 12857895 (Pubitemid 36871454)
8. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, et al. Vaccine 2010 28 950 957 10.1016/j.vaccine.2009.10.145 19925902
9. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. Thorner AR, Vogels R, Kaspers J, Weverling GJ, Holterman L, Lemckert AA, Dilraj A, McNally LM, Jeena PM, Jepsen S, et al. J Clin Microbiol 2006 44 3781 3783 10.1128/JCM.01249-06 17021110 (Pubitemid 46768807)
10. Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Appaiahgari MB, Saini M, Rauthan M, Jyoti, Vrati S, Microbes Infect 2006 8 92 104 10.1016/j.micinf.2005.05.023 16126425 (Pubitemid 43139296)
11. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Sun C, Zhang Y, Feng L, Pan W, Zhang M, Hong Z, Ma X, Chen X, Chen L, Vaccine 2011 29 3837 3841 10.1016/j.vaccine.2011.03.042 21447314
12. Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China. Yu B, Zhou Y, Wu H, Wang Z, Zhan Y, Feng X, Geng R, Wu Y, Kong W, Yu X, J Med Virol 2012 84 1408 1414 10.1002/jmv.23325 22825819
13. Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects. Yu B, Zhang Y, Zhan Y, Zha X, Wu Y, Zhang X, Dong Q, Kong W, Yu X, Oncol Rep 2011 26 255 264 21573500
14. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Dudareva M, Andrews L, Gilbert SC, Bejon P, Marsh K, Mwacharo J, Kai O, Nicosia A, Hill AV, Vaccine 2009 27 3501 3504 10.1016/j.vaccine.2009.03.080 19464527
15. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, et al. J Virol 2007 81 4654 4663 10.1128/JVI.02696-06 17329340 (Pubitemid 46668663)
16. The influence of innate and pre-existing immunity on adenovirus therapy. Zaiss AK, Machado HB, Herschman HR, J Cell Biochem 2009 108 778 790 10.1002/jcb.22328 19711370
17. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, et al. Lancet 2008 372 1894 1905 10.1016/S0140-6736(08)61592-5 19012957
18. Enrolling adolescents in HIV vaccine trials: reflections on legal complexities from South Africa. Slack C, Strode A, Fleischer T, Gray G, Ranchod C, BMC Med Ethics 2007 8 5 10.1186/1472-6939-8-5 17498316 (Pubitemid 46828958)
19. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Nganga D, Brandariz KL, Abbink P, et al. Vaccine 2011 29 5203 5209 10.1016/j.vaccine.2011.05.025 21619905
20. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM, J Virol 2008 82 546 554 10.1128/JVI.01689-07 17942545 (Pubitemid 350309169)
21. Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys. Sun Y, Bailer RT, Rao SS, Mascola JR, Nabel GJ, Koup RA, Letvin NL, J Virol 2009 83 10596 10604 10.1128/JVI.01170-09 19656883
22. Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. Hutnick NA, Carnathan D, Demers K, Makedonas G, Ertl HC, Betts MR, Vaccine 2010 28 1932 1941 10.1016/j.vaccine.2009.10.091 20188249
23. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, et al. J Virol 2003 77 6305 6313 10.1128/JVI.77.11.6305-6313.2003 12743287 (Pubitemid 36588400)
24. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al. Lancet 2008 372 1881 1893 10.1016/S0140-6736(08)61591-3 19012954
25. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L, Martin JE, Novik L, Chakrabarti BK, et al. J Infect Dis 2006 194 1638 1649 10.1086/509258 17109335 (Pubitemid 44901994)
26. Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines. Appaiahgari MB, Pandey RM, Vrati S, Clin Vaccine Immunol 2007 14 1053 1055 10.1128/CVI.00173-07 17596429